title: Male osteoporosis.
abstract: Osteoporosis is now recognized as a major threat to health in aging men. Morbidity and mortality, particularly following hip fracture, are substantial. Although trabecular bone loss starts in early adulthood, loss of cortical bone only seems to occur from midlife onwards. Declining bioavailable estradiol levels plays an integral role in male age-associated bone loss. Both pharmacologic and supportive care interventions are important for optimal care in men at an increased fracture risk.
authors.affiliation: Department of Medicine, Division of Endocrinology, College of Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA. drake.matthew@mayo.edu
authors.forename: Matthew T
authors.initials: MT
authors.lastname: Drake
authors.forename: Sundeep
authors.initials: S
authors.lastname: Khosla
mesh_terms: D000375:Aging; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001842:Bone and Bones / Q000187:drug effects; D020249:Hormone Replacement Therapy; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology* / Q000503:physiopathology; D058866:Osteoporotic Fractures / Q000209:etiology / Q000517:prevention & control; D053245:RANK Ligand / Q000037:antagonists & inhibitors; D012307:Risk Factors
chemical_list: D050071:Bone Density Conservation Agents; D053245:RANK Ligand